How Long Does PRP Injection Last for Knees: The Platelet-Concentration Duration Framework That Predicts Your Personal Timeline

Introduction: Why the ‘6–12 Months’ Answer Is Incomplete

Two patients sit in the same clinic with identical knee osteoarthritis diagnoses. Both receive platelet-rich plasma injections on the same day. Six months later, one patient reports that pain has returned, while the other continues to experience relief well past the 18-month mark. What explains this dramatic difference in outcomes?

Anyone researching how long PRP injection lasts for knees will encounter the same answer repeated across dozens of websites: six to twelve months. While technically accurate as a population average, this range obscures the specific variables that actually determine individual outcomes. The truth is far more nuanced, and understanding these variables can help patients set realistic expectations and optimize their treatment approach.

This article introduces the Platelet-Concentration Duration Framework, a layered model that accounts for four key variables: platelet concentration tier, BMI, disease duration, and injection protocol. By the end, readers will understand which variables apply to their situation and have an evidence-based lens for evaluating PRP rather than relying on a generic range.

The framework draws heavily from a 2025 meta-analysis published in the American Journal of Sports Medicine by Bensa and colleagues, which confirmed that PRP produced clinically superior improvement over placebo at all follow-up points through 12 months. This research, combined with multiple 2025 systematic reviews and retrospective studies, provides the evidentiary backbone for predicting personal timelines.

What PRP Actually Does Inside a Knee Joint

Platelet-rich plasma therapy involves a straightforward process. Blood is drawn from the patient, placed in a centrifuge to separate and concentrate the platelets, then injected directly into the knee joint. The concentrated platelets release growth factors including PDGF, TGF-β, VEGF, and IGF-1 that modulate inflammation, stimulate tissue repair, and improve synovial fluid quality.

Results are not immediate. Tissue regeneration is a biological process that unfolds over weeks and months. Most patients notice initial relief at three to six weeks, with peak benefits typically appearing at six to twelve months post-treatment. This timeline differs significantly from corticosteroid injections, which suppress inflammation acutely but wear off within two to three months. PRP works by promoting healing rather than masking symptoms, which explains its slower onset but longer duration.

According to Johns Hopkins Medicine, results are most noticeable after several weeks for joint injections and are not permanent. Additional injections may be recommended based on individual response.

PRP works best for mild to moderate osteoarthritis, classified as Kellgren-Lawrence grades I through III. The treatment cannot reverse severe joint degeneration or fully regrow lost cartilage. Patients with bone-on-bone arthritis have limited tissue substrate for the growth factors to stimulate.

The Platelet-Concentration Duration Framework: Four Variables That Predict Your Timeline

The framework operates as a four-variable model derived from 2025 meta-analyses and retrospective data. Each variable is independently quantified in peer-reviewed research, making this a data-driven approach rather than an anecdotal one.

The four variables are: platelet concentration tier, BMI, disease duration, and injection protocol.

The framework is additive in nature. Patients who score favorably on multiple variables are the ones who reach 18 or more months of relief. Those with multiple unfavorable variables may land closer to six months or experience non-response altogether.

Variable 1: Platelet Concentration Tier — The Single Biggest Driver of Duration

The 2025 Bensa et al. meta-analysis revealed a critical finding: high-platelet concentration PRP maintains clinically significant pain relief through 12 months, while low-platelet PRP shows significance only at the 6-month mark. This single variable may be the most important predictor of how long results will last.

Platelet concentration refers to the ratio of platelets in the prepared PRP relative to the patient’s baseline blood platelet count. Not all PRP preparations are equal. Some systems achieve concentrations four to six times baseline, while others produce minimal concentration above normal blood levels.

The leukocyte dimension adds another layer of complexity. According to a 2025 narrative review in the Journal of Clinical Medicine, leukocyte-poor PRP demonstrates superior pain relief and functional improvement compared to hyaluronic acid and corticosteroids, especially in mild to moderate knee osteoarthritis. Leukocyte-poor formulations also show better tolerance than leukocyte-rich versions.

A ScienceDirect study following 431 knee OA patients found that a single high-volume, very pure PRP injection provided significant improvement in function and pain over an 18-month follow-up period. This reinforces that purity and concentration matter tremendously.

The practical implication is clear: asking a provider about their platelet concentration protocol and whether they use leukocyte-poor or leukocyte-rich PRP is a legitimate and important question. If a provider cannot specify the platelet concentration of their preparation, that represents a red flag for duration outcomes. Patients researching their options can learn more about what to look for in a PRP treatment before committing to a protocol.

Variable 2: BMI — The 13.3% Rule

A 2025 retrospective study published in Frontiers in Physiology examined 140 knee OA patients and found a striking relationship: for every 1 kg/m² increase in BMI, PRP effectiveness decreased by 13.3%.

The biological rationale is multifaceted. Higher BMI increases mechanical load on the joint, promotes a pro-inflammatory systemic environment, and may dilute the concentration of growth factors relative to joint volume.

To quantify the impact practically: a patient at BMI 32 versus BMI 26 could see a meaningful difference in both the magnitude and duration of relief. A 2025 meta-analysis in the European Journal of Medical Research confirmed that patients with BMI below 30 kg/m² demonstrated more significant functional improvements.

BMI is a modifier, not a disqualifier. Patients with higher BMI can still benefit from PRP, but realistic expectations and potentially more aggressive protocols such as a triple-injection series may be warranted.

Weight management before and between PRP treatments is not just general health advice. It has a quantified impact on how long results will last.

Variable 3: Disease Duration — Why Earlier Intervention Extends Results

The same 2025 Frontiers in Physiology retrospective study revealed another critical finding: each 1-year increase in disease duration was associated with a 9.5% reduction in PRP effectiveness on WOMAC functional outcome scores.

The biological logic is straightforward. Longer disease duration means more cartilage loss, more chronic inflammation, and less remaining tissue for PRP growth factors to stimulate. Younger patients and those with shorter disease duration tend to experience longer-lasting results because their tissues retain greater healing capacity.

Patients who are waiting to see if symptoms worsen before trying PRP may be inadvertently reducing their potential duration of benefit. This represents a compelling reason for consideration-stage patients to act sooner rather than later. Understanding all alternatives to knee replacement surgery can help patients make more informed decisions about timing.

Variable 4: Injection Protocol — Single Shot vs. Triple Series

A 2025 review in the Open Access Journal of Sports Medicine found that three-injection regimens appear more effective than single injections for functional outcomes. The standard protocol involves a 3-injection series spaced 3 to 4 weeks apart.

Multiple injections sustain growth factor delivery over a longer biological window, reinforcing the regenerative cascade initiated by the first injection. The Frontiers in Physiology retrospective study confirmed that the number of injections significantly affected pain outcomes.

The ScienceDirect single-injection study provides a counterpoint: a single high-volume, very pure PRP injection can achieve 18-month outcomes. However, this requires exceptionally high platelet concentration and purity. For most patients, a triple series is the safer protocol choice for maximizing duration, especially if platelet concentration data is unavailable.

Ultrasound guidance also matters. Ultrasound-guided injection improves accuracy and treatment outcomes by confirming proper placement within the joint space. This represents a quality differentiator patients should ask about when choosing a provider.

Applying the Framework: What a Personal Timeline Might Look Like

The four variables combine to produce different duration outcomes based on individual profiles.

Favorable profile (high platelet concentration, BMI below 30, disease duration under 3 years, triple injection series): 12 to 18 or more months of clinically significant relief is a realistic expectation.

Moderate profile (moderate platelet concentration, BMI 30 to 35, disease duration 3 to 7 years, single injection): 6 to 12 months is the realistic range.

Challenging profile (low platelet concentration, BMI above 35, long disease duration, single injection): 3 to 6 months, with a higher likelihood of non-response.

Mayo Clinic reports a 60 to 70% success rate, meaning roughly 1 in 3 patients does not achieve the 50% improvement threshold. Setting realistic expectations is part of informed consent. This framework is a predictive tool, not a guarantee. Individual biology, injection technique, and post-care all contribute to final outcomes.

How PRP Duration Compares to Other Knee Injection Options

The three main injection categories for knee OA differ significantly in both onset and duration.

Onset timelines: Corticosteroids work within days. Hyaluronic acid takes 1 to 4 weeks. PRP takes 3 to 6 weeks. This slower onset is a trade-off for longer duration.

Duration comparison: Corticosteroids last 2 to 3 months. Hyaluronic acid lasts 4 to 6 months. PRP lasts 6 to 18 or more months depending on the framework variables.

A 2025 retrospective cohort study of 205 knees confirmed PRP offered the most sustained improvement in pain and function, followed by hyaluronic acid. Corticosteroids provided only short-term relief. A 2025 meta-analysis of 42 randomized controlled trials concluded that PRP leads to lower pain scores and better function than hyaluronic acid at 12-month follow-up, with differences exceeding the minimal clinically important difference.

Research published in 2025 by the Radiological Society of North America found that corticosteroid injections were associated with significantly greater structural knee damage over two years compared to hyaluronic acid. This finding has prompted many orthopedic specialists to reconsider corticosteroid use.

Patients comparing options may also want to review the evidence on hyaluronic acid injection for knee arthritis to understand where PRP fits within the broader treatment landscape.

PRP does not accelerate cartilage loss. Studies have confirmed no joint deterioration from PRP, in contrast to repeated steroid injections, which are linked to cartilage thinning over time.

The 7-Year Durability Argument: PRP’s Long-Term Value Case

A 7-year follow-up study published in Frontiers in Bioengineering and Biotechnology provides the most compelling long-term evidence available. PRP patients had lower re-intervention rates, lower pain scores, and significantly higher satisfaction (78.6%) compared to hyaluronic acid patients (55.8%) at minimum 7-year follow-up.

Lower re-intervention rates means fewer patients needed additional procedures, injections, or surgery over 7 years.

PRP is not covered by insurance and costs $500 to $2,000 per injection out of pocket. However, if PRP delays or prevents a knee replacement (which costs $30,000 to $50,000 or more and carries surgical risks), the long-term value calculation shifts significantly.

A 2021 study of 118 participants found that after an average 51.7-month follow-up, PRP continued to help improve symptoms of knee osteoarthritis. There is no evidence of harm from repeated treatments, and some patients opt for annual PRP injections for maintenance.

What to Do When PRP Wears Off: Repeat Treatments and Maintenance

PRP is not a one-time cure but a regenerative therapy that can be repeated as symptoms recur. For patients who initially respond well but experience symptom recurrence after 9 to 12 months, a second round of PRP is a clinically supported option.

Some patients schedule annual PRP injections as a proactive strategy to maintain joint health and delay disease progression.

Post-injection aftercare extends duration. Patients should avoid NSAIDs for up to 2 weeks before and 1 week after PRP application, as NSAIDs impair platelet function and reduce treatment effectiveness. Physical therapy serves as a complementary strategy; strengthening the muscles around the knee reduces mechanical load and can extend the functional benefits of PRP.

If PRP does not produce meaningful improvement after a full series, other options such as BMAC, stem cell therapy, exosome therapy, or hyaluronic acid should be discussed with a provider. Patients can explore how exosome vs stem cell therapy compares when evaluating next steps after PRP.

What the Guidelines Say — and Why the Evidence Is Outpacing Them

Major organizations including ACR, OARSI, and EULAR currently classify PRP as “uncertain” or “conditional” for knee OA. The lack of standardized PRP formulation, dosage, administration interval, and injection frequency makes it difficult for guideline bodies to issue strong recommendations. This is a limitation of the field, not evidence that PRP does not work.

A 2025 overview of systematic reviews in Frontiers in Physiology calls for large-scale, high-quality RCTs to validate findings and strengthen evidence.

However, the volume of recent evidence is substantial. A 2025 systematic review in Expert Opinion on Biological Therapy covering 766 studies and 75,834 patients found the evidence base for PRP has recently surpassed the number of studies on corticosteroids for knee OA. The American Orthopaedic Society for Sports Medicine notes that PRP is a safe, resource-conscious, and efficacious treatment for knee OA providing symptomatic relief and improved patient-reported outcomes.

PRP is not FDA-approved as a drug for knee OA, and insurance rarely covers it. Patients should make decisions with full awareness of both the promising evidence and the current guideline landscape. The absence of formal FDA approval does not mean the treatment is unsafe or ineffective; it reflects the regulatory pathway for biologics derived from a patient’s own blood.

Questions to Ask a Provider Before Getting PRP for the Knee

Patients can evaluate providers using the framework variables with these questions:

1. What platelet concentration will the PRP preparation achieve, and how is it measured?
2. Will leukocyte-poor or leukocyte-rich PRP be used, and why?
3. Based on the patient’s BMI and disease duration, what duration of relief is realistic?
4. Is a single injection or a series recommended, and what is the rationale?
5. Is the injection performed under ultrasound guidance to confirm accurate placement?
6. What post-injection protocol is recommended, including NSAID avoidance and physical therapy?
7. What are the signs that PRP is working, and at what point would a different approach be recommended?

Providers who can answer these questions specifically and with reference to current evidence are better positioned to optimize personal duration outcomes. Patients can also review what credentials to look for in a regenerative medicine doctor before selecting a clinic.

Conclusion: PRP Duration Is Not a Fixed Number — It Is a Variable That Can Be Influenced

The “6 to 12 months” average obscures a wide range of individual outcomes driven by four quantifiable variables. High-platelet PRP lasts through 12 months versus 6 months for low-platelet preparations. BMI reduces efficacy by 13.3% per kg/m². Disease duration reduces WOMAC scores by 9.5% per year. Triple series outperforms single injections.

The long-term value argument is compelling: 7-year data shows PRP patients have higher satisfaction and lower re-intervention rates than hyaluronic acid patients. Corticosteroids carry documented structural damage risk that PRP does not.

PRP is not for everyone. It is not FDA-approved for knee OA, not covered by insurance, and approximately 1 in 3 patients does not achieve the 50% improvement threshold.

Patients who understand the framework variables, choose a provider with high-concentration protocols and ultrasound guidance, optimize modifiable factors such as BMI and NSAID avoidance, and intervene earlier in their disease course are the ones most likely to achieve 12 to 18 or more months of meaningful relief.

How long does PRP injection last for knees? The answer is a personalized range, not a fixed number.

Ready to Find Out If PRP Is Right for Your Knee? Schedule a Consultation with Unicorn Bioscience

Understanding the variables that determine PRP duration is the first step. The next step is a personalized assessment with a qualified provider.

Unicorn Bioscience is a regenerative medicine clinic specializing in PRP and cellular therapies for knee osteoarthritis, with 8 locations across Texas, Florida, and New York. The practice offers precision ultrasound-guided injections, personalized treatment protocols based on individual patient factors including inflammation levels, age, injury type, and health goals, and same-day treatment availability for qualified candidates.

Unicorn Bioscience provides PRP alongside BMAC, stem cell therapy, exosome therapy, and hyaluronic acid. If PRP is not the optimal choice for a particular patient profile, other evidence-based options are available. Virtual and in-person consultations are offered to accommodate patients across geographies.

Schedule a consultation today at unicornbioscience.com or call (737) 347-0446 to speak with a specialist about PRP candidacy and expected duration of results.

Texas locations: Austin, Dallas, El Paso, Fort Worth, Houston, San Antonio

Florida: Boca Raton

New York: Manhattan

The Unicorn Bioscience team includes physicians with training from Johns Hopkins, and all treatments are administered within FDA regulatory frameworks.